Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
7.65    0.25 (3.38%)
Bid:
7.40
Ask:
7.90
Spread: 0.50 (6.757%)
Market Cap: £3.35m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Contract Update

19 Jul 2022 07:00

RNS Number : 8874S
Feedback PLC
19 July 2022
 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (as amended), which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018. Upon publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

Feedback plc

 

Contract Update

 

Feedback continues commercial strategy as it departs legacy PACS contract

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, announces that as part of its strategy to move the Company's operating model away from low margin legacy PACS (picture archiving and communication system) contracts, it is no longer providing PACS services for Royal Papworth Hospital NHS Foundation Trust ("Trust").

 

The Company has maintained the Cadran PACS service to support the Trust during a transitional phase whilst it identified a replacement provider and will continue to support the migration of underlying PACS data to the incoming provider, under contract until January 2023. The potential role of Bleepa at the site remains open as the Trust embeds with the new provider.

 

Having historically provided customers with solutions utilising TexRAD and Cadran, Feedback has evolved its proposition to focus on flagship product Bleepa, which targets a broader clinical audience and cross provider opportunities with increasingly visible revenue streams. Moving away from supplying PACS services will enable the Company to focus more resources at the growing opportunity for Bleepa, both domestically and internationally and has been a key strategic focus for the last two years.

 

Bleepa now contributes an increasing proportion of total revenues with growing commercialisation opportunities and routes to market matching the scalability of its product suite. This includes CareLocker and BleepaBox - which are providing increased exposure to the community diagnostic programme and tuberculosis screening programme in the UK and India respectively. Redirecting internal resource away from legacy products towards high margin growth opportunities is essential to delivering greater value for shareholders and underpins the Company's strategy to move into larger addressable market opportunities.

 

Further information on Feedback and its products can be found on the Company's website: https://fbkmed.com/feedback-plc/reports-and-presentations/

 

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Anesh Patel, CFO

+44 (0) 20 3997 7634

IR@fbk.com

 

Panmure Gordon (UK) Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

 

Walbrook PR Ltd

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome

07980 541 893 or 07748 325 236

 

 

About Feedback

 

Feedback plc is a specialist clinical communications business, with a mission to improve the efficiency and quality of communications for frontline clinicians and hospitals with a key focus on building solutions that enhance access to high quality patient data.

 

Feedback has developed a toolkit of clinical communications apps. Its core, regulatory approved product is Bleepa, a revolutionary medical imaging app enabling remote and secure communications between frontline clinicians and teams. CareLocker is an evolutionary GDPR compliant patient-centric cloud architecture - its proprietary technology enables an easy route to creation and mobilisation of individual healthcare records. Bleepa Box is a specialist tool to enable image transfer from remote settings to the Bleepa platform over mobile networks.

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based revenue model is expected to provide increasing levels of visibility as the Company grows its customer base.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDGPUAWMUPPGBR
Date   Source Headline
27th Apr 20202:00 pmRNSPrice Monitoring Extension
27th Apr 202011:05 amRNSSecond Price Monitoring Extn
27th Apr 202011:00 amRNSPrice Monitoring Extension
24th Apr 20207:00 amRNSGrant of Options
20th Apr 20207:00 amRNSBleepa rolled out at PAH NHS Trust for Covid-19
26th Mar 20203:52 pmRNSFeedback Medical to offer Bleepa for COVID-19
18th Feb 20207:00 amRNSInterim Results
3rd Feb 202012:21 pmRNSAppointment of Non-Executive Director
21st Jan 202010:30 amRNSChange of Registered Office
13th Jan 20207:00 amRNSLicence agreement with Imaging Engineering
19th Nov 20197:00 amRNSResult of AGM
18th Nov 20197:01 amRNSAGM Statement
18th Nov 20197:00 amRNSFirst Bleepa pilot study initiated with NHS Trust
24th Oct 20198:28 amRNSFinal Results: Revenue up 23%
17th Oct 20197:00 amRNSUpdate re Bleepa®
27th Sep 20192:52 pmRNSStatement re share price
4th Sep 20197:00 amRNSBleepa - the clinical messaging app - at NHS Expo
3rd Sep 20199:46 amRNSHolding(s) in Company
2nd Sep 201912:24 pmRNSHolding(s) in Company
2nd Sep 20197:00 amRNSHolding(s) in Company
30th Aug 20195:00 pmRNSTotal Voting Rights
29th Aug 20192:06 pmRNSResult of General Meeting
29th Aug 20197:00 amRNSBoard Changes
13th Aug 20192:45 pmRNSPosting of Circular and Notice of General Meeting
12th Aug 20197:00 amRNSProposed placing and subscription to raise £2m
7th Aug 201910:47 amRNSStatement re Online Commentary
26th Jul 201912:03 pmRNSBleepa - revolutionising clinical messaging
10th Jul 20197:00 amRNSOutcome of strategic review and trading update
10th Jun 20199:28 amRNSHolding(s) in Company
7th Jun 201910:07 amRNSHolding(s) in Company
25th Apr 20197:00 amRNSTrading update
9th Apr 20197:00 amRNSFeedback Medical CEO appointed Feedback plc CEO
14th Feb 20197:00 amRNSFeedback Medical appoints Dr Tom Oakley as CEO
24th Jan 20197:00 amRNSHalf-year Results
23rd Jan 20192:02 pmRNSResult of AGM
30th Nov 20185:00 pmRNSTotal Voting Rights
29th Nov 20182:37 pmRNSFinal Results
22nd Nov 201812:59 pmRNSFeedback retains industry standard certification
19th Nov 20182:56 pmRNSDirector/PDMR Shareholding
19th Nov 201811:49 amRNSHolding(s) in Company
16th Nov 20189:16 amRNSHolding(s) in Company
15th Nov 201811:35 amRNSResult of General Meeting
1st Nov 20183:11 pmRNSHolding(s) in Company
31st Oct 20185:00 pmRNSTotal Voting Rights
31st Oct 20184:15 pmRNSHolding(s) in Company
29th Oct 20182:44 pmRNSNotice of General Meeting
25th Oct 20187:00 amRNSProposed placing and subscription to raise £1.375m
22nd Oct 20187:00 amRNSExpansion of European customer base
3rd Oct 20187:00 amRNSTrading update
1st Oct 20187:00 amRNSAppointment of Joint Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.